Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALETTE
NCT06381661Phase 2Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2026
- Primary completion
- Aug 2028
- Modality
- Antibody Conjugates, Orthosteric Ligands, Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tocilizumab, baricitinib, anakinra, hydrocortisone, fludrocortisone and 8 more in sepsis (24 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: All-cause mortality at 28 days and Number of days alive without persistent life-supportive therapies at 28 days. Started Jul 2026; status: recruiting.
02
Drugs
tocilizumabbaricitinibanakinrahydrocortisonefludrocortisone
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT06381661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06381661.